Healthcare Professionals

Utilizing our robust scientific and clinical expertise

Autolus actively collaborates with healthcare professionals and various essential stakeholders to deliver gene therapies to patients. We are dedicated to engaging with individuals and organizations involved in the specific disease areas we focus on, and we continuously seek out new partnerships.

We are currently enrolling for several clinical trials. 

Program

Phase

Indication

Study Name

Further Information

Obe-cel

Pivotal

Adult ALL

FELIX

NCT04404660

Obe-cel

1

B-NHL

ALLCAR19 *

NCT02935257

Obe-cel

1

Pediatric B-ALL & B-NHL

AUTO1-PY1

NCT06173518

Obe-cel

1

PCNSL

CAROUSEL *

NCT04443829

Obe-cel

1

SLE

CARLYSLE

NCT05990751

AUTO1/22

1

Pediatric ALL

CARPALL *

NCT02443831

AUTO4

1

PTCL

LIBRAT1

NCT03590574

AUTO6NG

1

Neuroblastoma; Other tumor types

MAGNETO

NCT05990751

AUTO8

1

Multiple Myeloma

MCARTY *

NCT04795882

* Collaboration with UCL

For information on our open trials please speak with your doctor or contact us for more information [email protected].

Obe-cel

The company’s lead therapeutic candidate, obe-cel, is a potentially transformational treatment for adult Acute Lymphoblastic Leukemia. Obe-cel is an autologous CD19 CAR T cell therapy with a unique CD19 CAR.

Learn more

Expanded Access - Compassionate Use

Autolus is fully committed to the development of safe and effective therapies for patients and places a strong emphasis on prioritizing patient needs.

Learn more